Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea

Marín-Oto, M. ; Sanz-Rubio, D. ; Santamaría-Martos, F. ; Benitez, I. ; Simon, A. L. ; Forner, M. ; Cubero, P. ; Gil, A. ; Sánchez de la Torre, M. ; Barbe, F. ; Marín, J. M. (Universidad de Zaragoza)

Resumen: Background: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-inflammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap. Methods: Plasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers HNS], 84 healthy smokers HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap). Results: After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (- 12.5%, p = 0.005), COPD (- 14.8%, p < 0.001) and OSA-COPD overlap (- 12.3%, p = 0.02) compared with HNS. There were no differences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change significantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased significantly. Conclusions: The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD.

Idioma: Inglés

DOI: 10.1186/s12931-022-02092-9

Año: 2022

Publicado en: Respiratory Research 23 (2022), 163 [9 pp.]
ISSN: 1465-9921

Factor impacto JCR: 5.8 (2022)

Categ. JCR: RESPIRATORY SYSTEM rank: 15 / 66 = 0.227 (2022) - Q1 - T1

Factor impacto CITESCORE: 9.5 - Medicine (Q1)

Factor impacto SCIMAGO: 1.753 - Pulmonary and Respiratory Medicine (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER-FIS/PI18-01524
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-02175
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01940

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)